MEDI 0382

Drug Profile

MEDI 0382

Alternative Names: MEDI0382

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator MedImmune
  • Class Antihyperglycaemics; Obesity therapies
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 24 Feb 2017 MedImmune completes a phase I/II trial in Type 2 diabetes mellitus in Germany (NCT02548585) (EudraCT2014-003716-36)
  • 23 Feb 2017 Phase-II clinical trials in Obesity in Germany (SC) (MedImmune pipeline, February 2017)
  • 23 Feb 2017 Phase-II clinical trials in Type-2 diabetes mellitus in Germany (SC) (MedImmune pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top